Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0000899923-25-000037
Filing Date
2025-05-01
Accepted
2025-05-01 16:03:06
Documents
21
Effectiveness Date
2025-05-01

Document Format Files

Seq Description Document Type Size
1 S-8 forms-8mygn_may2025.htm S-8 74998
2 EX-107 ex107filingfeesexhibit.htm   iXBRL EX-FILING FEES 13437
3 EX-5.1 ex-51mintzopinion.htm EX-5.1 14798
4 EX-23.1 ex-231sx8consentmay2025.htm EX-23.1 2479
5 EX-99.1 ex-991xmyriadxdonnellyrsua.htm EX-99.1 58814
6 EX-99.2 ex-992myriadxdonnellypsuag.htm EX-99.2 60360
7 GRAPHIC image_0.jpg GRAPHIC 2393
8 GRAPHIC image_0a.jpg GRAPHIC 7669
9 GRAPHIC image_1a.jpg GRAPHIC 7104
10 GRAPHIC image_2a.jpg GRAPHIC 14011
  Complete submission text file 0000899923-25-000037.txt   395474

Data Files

Seq Description Document Type Size
23 EXTRACTED XBRL INSTANCE DOCUMENT ex107filingfeesexhibit_htm.xml XML 5453
Mailing Address 322 NORTH 2200 WEST SALT LAKE CITY UT 84116
Business Address 322 NORTH 2200 WEST SALT LAKE CITY UT 84116 801-584-3600
MYRIAD GENETICS INC (Filer) CIK: 0000899923 (see all company filings)

EIN.: 870494517 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-286901 | Film No.: 25902904
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)